Inventor
TRAXLER PETER
US28 patents
⚠️ This page may combine multiple inventors who share the name “TRAXLER PETER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
15 patentsUS6258812B1Jul 10, 2001
Phthalazines with angiogenesis inhibiting activity
NOVARTIS AG206 citations98
US5981533ANov 9, 1999
Pyrazole derivatives and processes for the preparation thereof
NOVARTIS AG104 citations98
US6140332AOct 31, 2000
Pyrrolopyrimidines and processes for the preparation thereof
NOVARTIS AG214 citations97
US6251911B1Jun 26, 2001
Pyrimidine derivatives and processes for the preparation thereof
NOVARTIS AG64 citations96
US6180636B1Jan 30, 2001
Substituted pyrrolopyrimidines and processes for their preparation
NOVARTIS AG78 citations96
US5686457ANov 11, 1997
Pyrrolopyrimidine derivatives having pharmacological activity
NOVARTIS AG92 citations96
US6710047B2Mar 23, 2004
Phthalazines with angiogenesis inhibiting activity
NOVARTIS AG25 citations92
US6514974B2Feb 4, 2003
Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activity
NOVARTIS AG15 citations92
US6140317AOct 31, 2000
Pyrrolopyrimidines and processes for their preparation
NOVARTIS AG37 citations92
US6096749AAug 1, 2000
Pyrrolopyrimidine derivatives having pharmacological activity
NOVARTIS AG42 citations92
US7244729B2Jul 17, 2007
4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
NOVARTIS AG6 citations74
US7323469B2Jan 29, 2008
7H-pyrrolo[2,3-d]pyrimidine derivatives
NOVARTIS AG4 citations63
US7723339B2May 25, 2010
Combination comprising a signal transduction inhibitor and an epothilone derivative
NOVARTIS AG2 citations58
US7390805B2Jun 24, 2008
4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
NOVARTIS AG0 citations52
US7879868B2Feb 1, 2011
Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
NOVARTIS AG0 citations50
CIBA GEIGY CORP
13 patentsUS5264431ANov 23, 1993
Polycyclic conjugates
CIBA GEIGY CORP24 citations92
US5491144AFeb 13, 1996
Substituted diaminophthalimides and analogues
CIBA GEIGY CORP18 citations80
US4681938AJul 21, 1987
Novel polycyclic hydrazones of rifamycins, their manufacture, and their pharmaceutical compositions for treating tuberculosis
CIBA GEIGY CORP13 citations74
US4551450ANov 5, 1985
Rifamycin hydrazones, pharmaceutical compositions containing them and their use
CIBA GEIGY CORP8 citations74
US4876258AOct 24, 1989
Biphenylyl compounds
CIBA GEIGY CORP10 citations73
US5663336ASep 2, 1997
Substituted diaminophthalimides and analogues
CIBA GEIGY CORP8 citations71
US4278665AJul 14, 1981
Papulacandin derivatives and pharmaceutical compositions containing same
CIBA GEIGY CORP11 citations69
US4374129AFeb 15, 1983
Antibiotically active aminopapulacandin derivatives
CIBA GEIGY CORP3 citations63
US4251517AFeb 17, 1981
Unsaturated or substituted methyl ethers having antibiotic activity
CIBA GEIGY CORP2 citations63
US4916126AApr 10, 1990
Diacyl derivatives of 4-(trialkylbenzyl)-piperazinyl compounds
CIBA GEIGY CORP5 citations62
US4411896AOct 25, 1983
Rifamycins, their compositions and use as antibiotics
CIBA GEIGY CORP1 citations50
US4376166AMar 8, 1983
Nocardia strain
CIBA GEIGY CORP1 citations50
US4298692ANov 3, 1981
Fermentation process for producing a rifamycin derivative
CIBA GEIGY CORP1 citations50